Positron radionuclide labeled Nectin-4 targeting probes PET imaging of malignant tumors

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500101262

Enrollment

Unknown

Registered

2025-04-22

Start date

2024-09-11

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Gold Standard:Lesion biopsy or surgical pathology

mpMRI and PET/CT

Index test:Targeting Nectin-4 probes PET/CT imaging

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with malignant tumors are included in the standard All must be satisfied before it can be included: (1) Voluntary signing of the informed consent form; (2) Age 18-75 years old, male or female, physical condition (ECOG PS) score of the Eastern United States Tumor Collaborative Group is 0~1; (3) Various malignant tumors that have undergone or are intended to undergo pathological biopsy (or undergo tumor surgical treatment) recently (within 2 months); (4) Pathological biopsy has been performed with pathological results or agree to carry out Nectin-4 immunohistochemical testing when necessary to verify the expression of Nectin-4; (5) According to RECIST version 1.1, there is at least one assessable tumor lesion. Criteria for selecting health control holders All must be satisfied to include: (1) Sign the informed consent form for examination and accept the positron nuclide-labeled Nectin-4 target probe PET/CT examination; (2) 18-75 years old, regardless of gender; (3) no previous history of malignant tumors; (4) normal blood routine, urinary routine, liver and kidney function, and coagulation function.

Exclusion criteria

Exclusion criteria: Exclusion criteria If any item is satisfied, it will be excluded: (1) Pregnant, pregnant and lactating women; (2) Suffering from claustrophobia or other mental diseases; (3) Have a history of severe allergies in the past, or are allergic to any active or non-active ingredients of the research drug; (4) It is judged by the researcher that it is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
The number of lesions;SUVmax;Adverse events;sensitivity;specificity;	—

Countries

China

Contacts

Public ContactPengcheng Ran

Guangdong Provincial Hospital of Chinese Medicine

cmurpc@163.com+86 137 5170 1540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026